Opinion|Videos|January 27, 2026
Real‑World “Time Toxicity” and Patient Impact: Lessons from ASH 2025 for Epcoritamab in Follicular Lymphoma
A recent ASH study highlights the impact of CAR T and bispecific therapies on patient time commitment and quality of life in treatment decisions.
Advertisement
Episodes in this series
A recent real‑world analysis presented at American Society of Hematology Annual Meeting (ASH 2025) examined “time toxicity” — the burden of frequent healthcare visits and therapy‑related appointments — in patients treated with Epcoritamab. The study compared fixed‑duration regimens (such as for some bispecific antibodies) to continuous, treat‑to‑progression approaches, such as CAR-T therapies.
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
Unexplained Pauses Hit Nearly Half of Monthly-Updated CDC Databases, Raising Transparency Concerns
2
5 Ongoing Phase 3 Trials in Hematologic Malignancies
3
CRC Becomes Leading Cause of Cancer-Related Death in Younger Adults, Highlighting Prevention Gaps
4
ACE Inhibitors Linked to Reduced Mortality in Patients with Idiopathic Pulmonary Fibrosis
5
